709 related articles for article (PubMed ID: 32460004)
21. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.
DeVito NC; Plebanek MP; Theivanthiran B; Hanks BA
Front Immunol; 2019; 10():2876. PubMed ID: 31921140
[TBL] [Abstract][Full Text] [Related]
22. Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells.
Anticoli S; Aricò E; Arenaccio C; Manfredi F; Chiozzini C; Olivetta E; Ferrantelli F; Lattanzi L; D'Urso MT; Proietti E; Federico M
J Mol Med (Berl); 2018 Feb; 96(2):211-221. PubMed ID: 29282521
[TBL] [Abstract][Full Text] [Related]
23. Exosomes and their roles in immune regulation and cancer.
Greening DW; Gopal SK; Xu R; Simpson RJ; Chen W
Semin Cell Dev Biol; 2015 Apr; 40():72-81. PubMed ID: 25724562
[TBL] [Abstract][Full Text] [Related]
24. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.
Zheng R; Kjaergaard J; Lee WT; Cohen PA; Shu S
Cancer Treat Res; 2007; 135():223-37. PubMed ID: 17953420
[No Abstract] [Full Text] [Related]
25. Functions of Exosomes in the Triangular Relationship between the Tumor, Inflammation, and Immunity in the Tumor Microenvironment.
Wang T; Nasser MI; Shen J; Qu S; He Q; Zhao M
J Immunol Res; 2019; 2019():4197829. PubMed ID: 31467934
[TBL] [Abstract][Full Text] [Related]
26. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
27. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.
Kang TH; Mao CP; Lee SY; Chen A; Lee JH; Kim TW; Alvarez RD; Roden RB; Pardoll D; Hung CF; Wu TC
Cancer Res; 2013 Apr; 73(8):2493-504. PubMed ID: 23418322
[TBL] [Abstract][Full Text] [Related]
29. Differentiation and Regulation of T
Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
Front Immunol; 2021; 12():669474. PubMed ID: 34012451
[TBL] [Abstract][Full Text] [Related]
30. The Yin and Yang of tumour-derived extracellular vesicles in tumour immunity.
Yamauchi T; Moroishi T
J Biochem; 2021 Mar; 169(2):155-161. PubMed ID: 33226400
[TBL] [Abstract][Full Text] [Related]
31. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
[TBL] [Abstract][Full Text] [Related]
33. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes.
Hiltbrunner S; Larssen P; Eldh M; Martinez-Bravo MJ; Wagner AK; Karlsson MC; Gabrielsson S
Oncotarget; 2016 Jun; 7(25):38707-38717. PubMed ID: 27231849
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy using dendritic cell-derived exosomes.
Amigorena S
Medicina (B Aires); 2000; 60 Suppl 2():51-4. PubMed ID: 11188932
[TBL] [Abstract][Full Text] [Related]
35. The functions and clinical applications of tumor-derived exosomes.
Shao Y; Shen Y; Chen T; Xu F; Chen X; Zheng S
Oncotarget; 2016 Sep; 7(37):60736-60751. PubMed ID: 27517627
[TBL] [Abstract][Full Text] [Related]
36. Tumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective.
Chen W; Jiang J; Xia W; Huang J
J Immunol Res; 2017; 2017():1073947. PubMed ID: 28642882
[TBL] [Abstract][Full Text] [Related]
37. Microfluidic on-demand engineering of exosomes towards cancer immunotherapy.
Zhao Z; McGill J; Gamero-Kubota P; He M
Lab Chip; 2019 May; 19(10):1877-1886. PubMed ID: 31044204
[TBL] [Abstract][Full Text] [Related]
38. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Hurwitz AA; Watkins SK
Cancer Immunol Immunother; 2012 Feb; 61(2):289-293. PubMed ID: 22237887
[TBL] [Abstract][Full Text] [Related]
39. The Biology of Cancer Exosomes: Insights and New Perspectives.
Ruivo CF; Adem B; Silva M; Melo SA
Cancer Res; 2017 Dec; 77(23):6480-6488. PubMed ID: 29162616
[TBL] [Abstract][Full Text] [Related]
40. Regulation of tumor immunity by tumor/dendritic cell fusions.
Koido S; Homma S; Hara E; Namiki Y; Takahara A; Komita H; Nagasaki E; Ito M; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2010; 2010():516768. PubMed ID: 21048993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
